Accueil   Diary - News   All news bioMérieux serology tests for SARS-CoV-2 on VIDAS® undergo validation preceding imminent launch

bioMérieux serology tests for SARS-CoV-2 on VIDAS® undergo validation preceding imminent launch

 

 

 

Marcy l’Étoile, France – May 06, 2020 – bioMérieux, a world leader in the field of in vitro diagnostics, today announced performance validation and the upcoming launch of VIDAS® anti-SARS-CoV-2 serology tests to detect antibodies in people who have been exposed to the SARS-CoV-2 that causes the COVID-19 disease.

 

Building on years of experience in developing immunoassays, bioMérieux worked closely with several hospitals to develop and validate the performances of two tests. VIDAS® antiSARS-CoV-2 IgM and anti-SARS-CoV-2 IgG will identify in less than 30 minutes the presence of antibodies in people who have been infected with SARS-CoV-2. In this context, clinical specificity is particularly important to ensure that testing of uninfected individuals consistently shows a negative result. Both VIDAS® anti-SARS-CoV-2 IgM and anti-SARS-CoV-2 IgG demonstrated excellent clinical specificity data.

 

 

Read the press release